Brief: Lineage Announces Worldwide License Agreement With Immunomic Therapeutics For An Allogeneic Cell-Based Cancer Immunotherapy Based On Its Vac Platform

Lineage Cell Therapeutics

20/04/2021 13:37

April 20 (Reuters) - Lineage Cell Therapeutics Inc  LCTX.A :
    * LINEAGE ANNOUNCES WORLDWIDE LICENSE AGREEMENT WITH
IMMUNOMIC
THERAPEUTICS FOR AN ALLOGENEIC CELL-BASED CANCER IMMUNOTHERAPY
BASED ON ITS VAC PLATFORM
    * LINEAGE CELL THERAPEUTICS INC - AS PART OF DEAL CO TO
RECEIVE $2
MILLION UPFRONT & UP TO $67 MILLION IN DEVELOPMENT & COMMERCIAL
MILESTONES PLUS ROYALTIES
    * LINEAGE CELL THERAPEUTICS INC - AS PER DEAL IMMUNOMIC WILL
BE
RESPONSIBLE FOR FUTURE CLINICAL DEVELOPMENT AND
COMMERCIALIZATION COSTS

Source text for Eikon:  ID:nBw4vV6b8a 
Further company coverage:  LCTX.A 

 ((Reuters.Briefs@thomsonreuters.com;))